Answers are grounded in this paper and cite their sources.
Cordyceps militaris offers a cultivable source of cordycepin, a pharmaceutically relevant nucleoside. This review integrates evidence on cultivation, cordycepin biosynthesis and regulation, artificial intelligence and omics applications, recovery, and biological activities, with emphasis on reproducible production and pharmaceutical development. Solid-state and submerged cultivation serve different production targets; however, cordycepin yield and product quality vary with strain, substrate, developmental stage, and process conditions. Cordycepin production depends on biosynthetic activity and protection against deamination associated with the cns1–cns4 cluster, precursor supply, and environmental regulation rather than on gene expression alone. Genetic engineering, metabolic modelling, multi-omics, machine learning, and process monitoring have supported production improvement, pathway analysis or prediction, but these approaches remain poorly integrated. The reviewed studies do not demonstrate validated online cordycepin estimation or autonomous control. Recovery methods involve trade-offs among yield, purity, cost, and throughput, highlighting the need for consistent product specifications. Cordycepin shows anticancer, anti-inflammatory, and antioxidant activities, although evidence remains preclinical and limited by variable experimental exposures, incomplete mechanistic validation, and insufficient pharmacokinetic and clinical data. Future progress requires standardized strains and cultivation protocols, causal metabolic validation, externally validated predictive models, integrated process control, scalable recovery, and translational evaluation.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: